Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 191,762 shares at $0.42 ($87K) on 2026-05-21, disclosed to the SEC on 2026-05-26.
Scheduled sale ($87k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.42 | 36,387 | $15K | 17.7% |
| 2 | $0.45 | 87,425 | $39K | 45.4% |
| 3 | $0.47 | 67,950 | $32K | 36.9% |
| Total | $0.45 avg | 191,762 | $87K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |